Jakob, a Danish citizen, who will be based in Stockholm, will join Elekta in August to begin his onboarding and transition into his role, working closely with the current Acting CEO, Jonas Bolander, and the management team.

Jakob Just-Bomholt has a strong track record as a highly experienced international executive, having held various senior management positions. Most recently, he served as CEO of 3Shape, a Danish global innovator in 3D scanning and CAD/CAM software for the dental industry. Before that, he was a senior executive within Falck A/S and A/P Moller Maersk.

Dr Laurent Leksell, Elekta’s Founder and Chairman of the Board of Directors, said: "We are delighted to welcome Jakob Just-Bomholt to Elekta. His strategic leadership and international experience, combined with a proven ability to drive profitable growth and global expansion through customer-focused innovation and operational excellence, make him very well-suited to lead Elekta forward. The Board is confident in Jakob’s ability to guide the company into its next chapter and deliver value to our shareholders, customers, and the cancer patients we serve around the world.”

Jakob Just-Bomholt commented: "I am honored to join Elekta, a company with a proud legacy and a powerful mission to improve the lives of people with cancer. Radiation therapy plays a vital role in modern oncology, and I look forward to working with the talented team at Elekta to continue delivering life-changing solutions to patients around the world. Elekta holds a strong market position, industry leading product portfolio, and considerable growth potential. I look forward to guiding the company in delivering long-term value for all our stakeholders."

# # #

For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com  
Time zone: CET: Central European Time

Peter Nyquist, Vice President, Head of Investor Relations
Tel: +46 70 575 2906, e-mail: peter.nyquist@elekta.com
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 19:00 CEST on June 9, 2025.

About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com.